Rapt Therapeutics Inc
NASDAQ:RAPT
Income Statement
Earnings Waterfall
Rapt Therapeutics Inc
Income Statement
Rapt Therapeutics Inc
| Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||||||||||
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
1
N/A
|
2
+136%
|
4
+69%
|
5
+34%
|
5
+6%
|
5
-8%
|
4
-11%
|
4
-13%
|
3
-15%
|
3
+1%
|
2
-30%
|
2
-33%
|
1
-42%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | |||||||||||||||||||||||||||||
| Operating Expenses |
(37)
|
(38)
|
(41)
|
(40)
|
(44)
|
(48)
|
(51)
|
(57)
|
(58)
|
(62)
|
(65)
|
(69)
|
(73)
|
(77)
|
(80)
|
(82)
|
(87)
|
(97)
|
(106)
|
(118)
|
(127)
|
(128)
|
(129)
|
(115)
|
(136)
|
(123)
|
(113)
|
(113)
|
|
| Selling, General & Administrative |
(5)
|
(6)
|
(7)
|
(7)
|
(9)
|
(10)
|
(10)
|
(12)
|
(13)
|
(13)
|
(14)
|
(15)
|
(16)
|
(17)
|
(18)
|
(20)
|
(20)
|
(21)
|
(23)
|
(25)
|
(26)
|
(28)
|
(28)
|
(27)
|
(29)
|
(28)
|
(29)
|
(30)
|
|
| Research & Development |
(32)
|
(32)
|
(34)
|
(33)
|
(35)
|
(38)
|
(40)
|
(45)
|
(45)
|
(49)
|
(51)
|
(54)
|
(57)
|
(60)
|
(61)
|
(62)
|
(67)
|
(76)
|
(83)
|
(94)
|
(101)
|
(100)
|
(101)
|
(88)
|
0
|
(94)
|
(84)
|
(83)
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(107)
|
0
|
0
|
0
|
|
| Operating Income |
(37)
N/A
|
(38)
-3%
|
(41)
-7%
|
(40)
+1%
|
(44)
-8%
|
(47)
-8%
|
(49)
-3%
|
(53)
-9%
|
(53)
0%
|
(57)
-7%
|
(60)
-6%
|
(64)
-7%
|
(69)
-8%
|
(73)
-6%
|
(76)
-4%
|
(79)
-4%
|
(86)
-8%
|
(97)
-13%
|
(106)
-10%
|
(118)
-12%
|
(127)
-7%
|
(128)
-1%
|
(129)
0%
|
(115)
+11%
|
(136)
-18%
|
(123)
+10%
|
(113)
+8%
|
(113)
+0%
|
|
| Pre-Tax Income | |||||||||||||||||||||||||||||
| Total Other Income |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
1
|
2
|
4
|
7
|
9
|
10
|
10
|
9
|
7
|
6
|
6
|
7
|
7
|
|
| Pre-Tax Income |
(36)
N/A
|
(37)
-3%
|
(40)
-7%
|
(39)
+1%
|
(42)
-8%
|
(46)
-9%
|
(48)
-3%
|
(52)
-9%
|
(52)
+0%
|
(56)
-7%
|
(60)
-7%
|
(64)
-7%
|
(69)
-8%
|
(73)
-6%
|
(76)
-4%
|
(79)
-3%
|
(84)
-6%
|
(93)
-10%
|
(99)
-7%
|
(109)
-10%
|
(117)
-7%
|
(119)
-1%
|
(121)
-2%
|
(108)
+11%
|
(130)
-20%
|
(117)
+10%
|
(106)
+9%
|
(106)
+1%
|
|
| Net Income | |||||||||||||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(36)
|
(37)
|
(40)
|
(39)
|
(43)
|
(47)
|
(49)
|
(53)
|
(53)
|
(56)
|
(60)
|
(64)
|
(69)
|
(73)
|
(76)
|
(79)
|
(84)
|
(93)
|
(99)
|
(109)
|
(117)
|
(119)
|
(121)
|
(108)
|
(130)
|
(117)
|
(106)
|
(106)
|
|
| Net Income (Common) |
(36)
N/A
|
(37)
-3%
|
(40)
-7%
|
(39)
+1%
|
(43)
-10%
|
(47)
-9%
|
(49)
-4%
|
(53)
-10%
|
(53)
+1%
|
(56)
-6%
|
(60)
-7%
|
(64)
-7%
|
(69)
-8%
|
(73)
-6%
|
(76)
-4%
|
(79)
-3%
|
(84)
-6%
|
(93)
-10%
|
(99)
-7%
|
(109)
-10%
|
(117)
-7%
|
(119)
-1%
|
(121)
-2%
|
(108)
+11%
|
(130)
-20%
|
(117)
+10%
|
(106)
+9%
|
(106)
+1%
|
|
| EPS (Diluted) |
-12.71
N/A
|
-13.04
-3%
|
-13.89
-7%
|
-13.78
+1%
|
-15.12
-10%
|
-16.14
-7%
|
-16.01
+1%
|
-17.46
-9%
|
-17.53
0%
|
-18.11
-3%
|
-18.75
-4%
|
-17.36
+7%
|
-20.21
-16%
|
-19.79
+2%
|
-19.58
+1%
|
-18.71
+4%
|
-20.61
-10%
|
-19.36
+6%
|
-20.6
-6%
|
-22.7
-10%
|
-24.37
-7%
|
-24.54
-1%
|
-24.95
-2%
|
-22.27
+11%
|
-25.51
-15%
|
-4.33
+83%
|
-3.95
+9%
|
-3.91
+1%
|
|